Related Experiment Videos
Piracetam reverses hippocampal membrane alterations in Alzheimer's disease
G P Eckert1, N J Cairns, W E Müller
1Department of Pharmacology, Biocenter, University of Frankfurt, Federal Republic of Germany.
Abstract:
The in vitro effects of piracetam treatment on the fluidity of membranes from the hippocampus of Alzheimer's Disease patients (AD) and non-demented controls were studied. Hippocampal membranes of AD patients showed a significant lower hydrocarbon core fluidity compared with membranes from elderly non-demented controls. Preincubation with piracetam enhanced the hydrocarbon core fluidity of hippocampal membranes from AD-patients as well as elderly controls in a concentration depending fashion, although the effect was more pronounced for the AD membranes. In the presence of piracetam, the difference of the membrane fluidity between AD and control membranes was not longer apparent.
Insights
Piracetam treatment improved membrane fluidity in the hippocampus for both Alzheimer's Disease (AD) patients and controls. This suggests piracetam may help normalize membrane function in AD by enhancing fluidity.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's Disease (AD) is associated with altered neuronal membrane properties.
- Hippocampal membranes in AD patients exhibit reduced hydrocarbon core fluidity compared to controls.
Purpose of the Study:
- To investigate the in vitro effects of piracetam on hippocampal membrane fluidity in Alzheimer's Disease (AD) patients.
- To compare the impact of piracetam on membrane fluidity between AD and non-demented control groups.
Main Methods:
- In vitro study utilizing hippocampal membranes from AD patients and elderly non-demented controls.
- Measurement of hydrocarbon core fluidity using biophysical techniques.
- Treatment with varying concentrations of piracetam.
Main Results:
- Hippocampal membranes from AD patients demonstrated significantly lower hydrocarbon core fluidity than controls.
- Piracetam enhanced membrane fluidity in a concentration-dependent manner for both AD and control groups.
- The enhancing effect of piracetam was more pronounced in AD membranes, normalizing fluidity differences between groups.
Conclusions:
- Piracetam treatment in vitro increases hippocampal membrane fluidity.
- Piracetam may restore normal membrane fluidity in Alzheimer's Disease (AD) by counteracting the reduced fluidity observed in AD patients.
- These findings suggest a potential therapeutic role for piracetam in modulating membrane biophysical properties in AD.